Yip, Terry Cheuk-Fung
Wong, Grace Lai-Hung
Tse, Yee-Kit
Yuen, Becky Wing-Yan
Luk, Hester Wing-Sum
Lam, Marco Ho-Bun
Li, Michael Kin-Kong
Loo, Ching Kong
Tsang, Owen Tak-Yin
Tsang, Steven Woon-Choy
Chan, Henry Lik-Yuen
Wing, Yun-Kwok
Wong, Vincent Wai-Sun
Article History
Received: 6 January 2020
Accepted: 15 April 2020
First Online: 29 April 2020
Ethics approval and consent to participate
: This study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (Ref. No. 2018.230).The Ethics Committee waived the need for written consent as this was a retrospective study using deidentified registry data.
: This paper does not involve individual participant’s data.
: TCFY has served as a speaker for Gilead Sciences. GLHW has served as an advisory committee member for Gilead Sciences, and as a speaker for Abbott, Abbvie, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen and Roche. HLYC has served as an advisory committee member for AbbVie, Aligos, Aptorum, Altimmune, Arbutus, ContraVir, Intellia, Janssen, Gilead, Medimmune, Roche, Vaccitech, VenetoRx, Vir Biotechnology and GRAIL; and as a speaker for AbbVie, Gilead and Roche. VWSW has served as an advisor/consultant for 3 V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Echosens, Gilead Sciences, Janssen, Novartis, Novo Nordisk, Perspectum Diagnostics, Pfizer and Terns; and a speaker for Bristol-Myers Squibb, Echosens, Gilead Sciences and Merck. GLHW, HLYC and VWSW have received research grants from Gilead Sciences. The other authors report no conflict of interests.